Double-digit recurring revenue growth in H1 2026 was driven by Winlevi®, Lialda®, and CDMO, with strong cash reserves and no debt. Regulatory progress in dermatology and GI pipelines, and expansion of the GI Genius™ platform, support reaffirmed full-year guidance.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.